Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Andexanet alfa for the reversal of anticoagulation: Dutch practice data.

Research and practice in thrombosis and haemostasis·2026

Same author

Neural network reveals platelet age from fluorescence microscopy images.

Platelets·2026

Same author

The Year in Coagulation and Transfusion: Selected Highlights.

Journal of cardiothoracic and vascular anesthesia·2026

Same author

Thrombophilia Screening in Young Patients With Cryptogenic Ischemic Stroke.

Stroke·2026

Same author

Family history of stroke and cardiovascular diseases in early-onset cryptogenic ischaemic stroke.

European stroke journal·2026

Same author

Timeless therapeutics: cardiac indications for vitamin K antagonists in clinical practice.

Heart (British Cardiac Society)·2026

Search research articles

Related Experiment Video

Updated: Jul 27, 2025

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Coagulation biomarkers for ischemic stroke.

Aarazo Barakzie¹, A J Gerard Jansen¹, Hugo Ten Cate^2,3

¹Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Research and Practice in Thrombosis and Haemostasis

|June 5, 2023

Summary

Coagulation biomarkers show potential for predicting ischemic stroke (IS) risk and outcomes. While many markers are associated with IS, further research is needed to confirm their therapeutic and predictive utility.

Keywords:

coagulation biomarkers immunothrombosis inflammation ischemic stroke prognosis therapy

More Related Videos

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Related Experiment Videos

Last Updated: Jul 27, 2025

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Area of Science:

Cardiovascular Medicine
Hematology
Neurology

Background:

Ischemic stroke (IS) presents significant morbidity and mortality.
Predicting IS risk and patient outcomes remains challenging.
Coagulation marker imbalance may influence IS progression and prognosis.

Purpose of the Study:

To review associations between coagulation biomarkers and IS.
To evaluate biomarkers for IS risk, severity, and outcomes.
To discuss recent findings from the 2022 ISTH Congress.

Main Methods:

Review of prospective population studies, case-control studies, and acute-phase IS studies.
Analysis of coagulation biomarkers from hemostasis, inflammation, and immunothrombosis systems.
Discussion of data presented at the 2022 ISTH Congress.

Main Results:

Numerous coagulation and inflammation biomarkers are linked to IS.
Strongest evidence suggests roles for beta-thromboglobulin, von Willebrand factor, factor VIII, fibrinogen, thrombin-activatable fibrinolysis inhibitor, D-dimer, and neutrophil extracellular traps.
Current evidence is insufficient for therapeutic application in predicting IS risk or outcomes.

Conclusions:

Several coagulation biomarkers are promising candidates for IS prediction.
Extensive research and large-scale validation are required.
Biomarker application in clinical practice for IS requires further investigation.